LONDON, March 14 (Reuters) - AstraZeneca Plc said on Tuesday it believed the first option payment due to Merck & Co Inc in 2008 under a complex marketing partnership scheme between the firms was unlikely to exceed a net $3.3 billion.
LONDON, March 14 (Reuters) - AstraZeneca Plc said on Tuesday it believed the first option payment due to Merck & Co Inc in 2008 under a complex marketing partnership scheme between the firms was unlikely to exceed a net $3.3 billion.
